Executive Summary of the Malaysian Consensus on the Management of Acute and Persistent Hyperkalaemia: A Multidisciplinary Approach

Hyperkalaemia (HyperK+) is a potentially life-threatening condition that poses significant challenges in both acute and chronic care, especially for patients with chronic kidney disease, heart failure and diabetes mellitus. While renin-angiotensin-aldosterone system inhibitors (RAASi) are guideline-directed medical therapy known for their cardiorenal benefits, concerns about the increased risk of hyperK+ associated with these medications have hindered their optimal use. Despite these challenges, ambiguity remains regarding the management of hyperK+, highlighting the need for a standardised approach. This Malaysian consensus provides evidence-based guidelines for managing acute and persistent hyperK+ tailored to the local healthcare context.